UC SAN DIEGO NEWS CENTER 20/07/16 Synthetic Biology Used to Limit Bacterial Growth and Coordinate Drug Release. Researchers at the University of California San Diego and the Massachusetts Institute of Technology (MIT) have come up with a strategy for using synthetic biology in therapeutics.
The approach enables continual production and release of drugs at disease sites in mice while simultaneously limiting the size, over time, of the populations of bacteria engineered to produce the drugs. The findings are published in the July 20 online issue of Nature. UC San Diego researchers led by Jeff Hasty, a professor of bioengineering and biology, engineered a clinically relevant bacterium to produce cancer drugs and then self-destruct and release the drugs at the site of tumors.
The team then transferred the bacterial therapy to their MIT collaborators for testing in an animal model of colorectal metastasis. The new study offers a therapeutic approach that minimizes damage to surrounding cells. Limiting the bacterial population Programmed cycles of bacterial drug delivery. Developing a strategy. NATURE 23/02/16 Synthetic biology’s first malaria drug meets market resistance. William Daniels/Panos The plant Artemisia annua (pictured being harvested in Tanzania) was the only source of artemisinin before biochemists invented a synthetic route.
When Paris-based pharmaceutical giant Sanofi started to sell malaria drugs made with the help of genetically engineered yeast in 2014, the move was hailed as a triumph for synthetic biology. The yeast was fermented in a vat to produce a chemical that Sanofi converted into artemisinin, which is used to make leading malaria treatments called artemisinin-based combination therapies (ACTs). Many hoped that the process would offer a cheap and plentiful supply of drugs to tackle a disease that claims almost half a million lives worldwide every year. Yet Sanofi produced no ‘semi-synthetic’ artemisinin (SSA) at all in 2015, Nature has learned. The synthetic-biology route promised to end this rollercoaster by providing a stable and reliable source of artemisinin.
“In reality, that has not happened,” says Yadav. Frederic J. Adv Drug Deliv Rev. 2016 Apr 18. pii: S0169-409X(16)30105-3. Synthetic biology platform technologies for antimicrobial applications. A Department of Biomedical Engineering, Boston University, Boston, MA 02215, USAb Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USAc Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USAd Synthetic Biology Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USAe Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USAf Harvard-MIT Program in Health Sciences and Technology, Cambridge, MA 02139, USAg Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA Received 6 November 2015, Revised 8 March 2016, Accepted 6 April 2016, Available online 18 April 2016 Choose an option to locate/access this article: Check if you have access through your login credentials or your institution Check access.
CURRENT OPINION IN MICROBIOLOGY 03/07/14 Bacteriophage-based synthetic biology for the study of infectious diseases. INSTITUTE ON SCIENCE FOR GLOBAL POLICY – OCT 2011 - Synthetic Biology: A New Weapon in Our War Against Infectious Diseases. Synthetic Biology: A New Weapon in Our War Against Infectious Diseases Professor, J.
Craig Venter Institute Summary Prior to the modern age, infectious diseases were the principal cause of human morbidity and mortality. The invention and widespread use of vaccines and antibiotics, along with advances in public health, sanitation, and nutrition, expanded human lifespan. MASSACHUSETTS INSTITUTE OF TECHNOLOGY - FEV 2008 - Combating biofilms and antibiotic resistance using synthetic biology. Biotechnol J. 2011 Jul;6(7):812-25. Engineering antibiotic production and overcoming bacterial resistance. INSTITUTE OF BIOLOGY (Freiburg, Germany) 18/03/10 Présentation : Synthetic Biology in Drug Discovery and Combating Drug Resistan.
Bioeng Bugs. 2011 Jul 1;2(4):230-3. . The future of industrial antibiotic production: from random mutagenesis to synthetic biolo. EUROPEAN SCIENCE FOUNDATION - OCT 2011 - ESF-EMBO Symposium Synthetic Biology of Antibiotic Production 2-7 October 2011. This conference will focus on the advancement of synthetic biology, especially its application in the field of antibiotic production in filamentous fungi and actinomycete bacteria, including the implementation and modification of complex biosynthesis pathway modules in existing and new production hosts.
Antibiotics production is regulated by complex networks and involves intricate multi-step biosynthetic machineries, as well as major reorganization of primary metabolic fluxes to redirect cellular metabolic resources towards their biosynthesis. The urgent need for new antibiotics caused by the accelerating emergence of multi-drug resistant pathogens worldwide has led to a strong interest in the research community for decidedly novel approaches, collectively referred to as Synthetic Biology. To learn more about the conference, please see the Final Programme(PDF) List of Invited Speakers and Accepted Participants List of Accepted Short Talks (PDF - last updated 22 September)